HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.
HIV-1 tropism assays play a crucial role in determining the response to CCR5 receptor antagonists. Initially, phenotypic tests were used, but limited access to these tests prompted the development of alternative strategies. Recently, genotyping tropism has been validated using a Canadian technology in clinical trials investigating the use of maraviroc in both experienced and treatment-naive patients. The present guidelines review the evidence supporting the use of genotypic assays and provide recommendations regarding tropism testing in daily clinical management.
Centre hospitalier de l'Université de Montréal; ; Laboratoire de santé publique du Québec;
Cécile
C
Tremblay
Centre hospitalier de l'Université de Montréal; ; HIV Genotyping Program;
Isabelle
I
Hardy
McGill University Health Centre; ; Advisory Committee on the Clinical Management of Persons Living with HIV;
Richard
R
Lalonde
Centre hospitalier de l'Université de Montréal; ; Advisory Committee on the Clinical Management of Persons Living with HIV; ; Clinique médicale l'Actuel;
Benoit
B
Trottier
Advisory Committee on the Clinical Management of Persons Living with HIV; ; Service de lutte contre les infections transmissibles sexuellement et par le sang, ministère de la Santé et des Services sociaux;
Irina
I
Tsarevsky
Advisory Committee on the Clinical Management of Persons Living with HIV; ; Programme national de mentorat sur le VIH-sida;
Louis-Philippe
LP
Vézina
Centre hospitalier de l'Université de Montréal; ; HIV Genotyping Program;
Michel
M
Roger
McGill AIDS Centre; ; McGill University, Montreal, Quebec;
Mark
M
Wainberg
Centre hospitalier de l'Université de Montréal; ; Advisory Committee on the Clinical Management of Persons Living with HIV; ; Clinique médicale du Quartier Latin.
Jean-Guy
JG
Baril
CCR5; HIV; Maraviroc; Tropism